- Sushmita Choudhury
- Updated: Jul 1, 2021, 15:06 IST IST
Having received emergency use authorisation, US-based biotechnology major Moderna is all set to bring in the country's first mRNA vaccine
India will soon get its fourth Covid-19 vaccine after Covishield, Covaxin and Sputnik V. On June 29, US-based biotechnology major Moderna was granted emergency use authorisation (EUA) for its vaccine based on mRNA technology. According to NITI Aayog member (health) VK Paul, the regulatory clearance potentially opens up a clear possibility of the vaccine being imported into the country in the near future. He added that the government is also making efforts to bring in other internationally developed vaccines, specifically Pfizer and Johnson & Johnson.
Indian pharma major Cipla will “facilitate” the import of the Moderna vaccine. “This is not a commercial or supply deal, and we do not distribute this consignment either,” said Cipla’s global CEO Umang Vohra. However, Cipla is reportedly also pursuing a separate tie-up with the US firm to undertake large-scale fill-and-finish, distribution and commercialisation of this vaccine.
Indian pharma major Cipla will “facilitate” the import of the Moderna vaccine. “This is not a commercial or supply deal, and we do not distribute this consignment either,” said Cipla’s global CEO Umang Vohra. However, Cipla is reportedly also pursuing a separate tie-up with the US firm to undertake large-scale fill-and-finish, distribution and commercialisation of this vaccine.